Tryptamine Therapeutics Ltd. is gearing up to enter the clinic with lead compound TRP-8803, an intravenous-infused psilocybin therapy, in patients with binge eating disorder in conjunction with ...
Tryptamine inks deal with world leading psychedelic researchers to validate a new EEG-based biomarker platform Deal leverages entropy research to predict and optimise therapeutic use of Tryptamine’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback